Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib + thalidomide + dexamethasone for relapsed/refractory multiple myeloma
ACTRN12616000894493Phase 2Completed
- Sponsor
- Professor Andrew Spencer
- Start
- Dec 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixazomib, thalidomide and dexamethasone in multiple myeloma (MM), sponsored by Professor Andrew Spencer. Primary endpoints: Overall response rate and Safety and tolerability. Started Dec 2016; status: completed.
02
Drugs
ixazomibthalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12616000894493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000894493.